Submitted by Anonymous (not verified) on 22 November 2024 - 10:40
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0482/2023
Source: